NCT03519438 is a clinical trial of Mepitel in Breast Cancer, sponsored by Mayo Clinic.

Who is sponsoring NCT03519438?

NCT03519438 is sponsored by Mayo Clinic.

What drugs are being tested in NCT03519438?

Interventions in NCT03519438: Mepitel.

What condition does NCT03519438 study?

NCT03519438 studies Breast Cancer.

Is NCT03519438 still recruiting?

NCT03519438 is currently completed. Last updated 20 May 2022.

Last reviewed 2022-05-20 · How we verify

NCT03519438

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis

Completed Last updated 20 May 2022

What this trial tests

trial testing Mepitel in Breast Cancer in 40 participants. Completed in 25 November 2019.

Timeline

11 April 2018

Primary endpoint
25 November 2019

25 November 2019

Quick facts

Lead sponsor	Mayo Clinic
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	11 April 2018
Primary completion	25 November 2019
Estimated completion	25 November 2019
Sites	1 location across United States

Drugs / interventions tested

Mepitel

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to examine alterations in the skin microbiome that occur during radiation therapy. The study design will examine changes secondary to ionizing radiation, and correlate these changes with the development and severity of radiation dermatitis. The goal is to improve understanding of the mechanism of radiation dermatitis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Role of Gut Microbiota in Breast Cancer and Drug Resistance.
Viswanathan S, Parida S, Lingipilli BT, Krishnan R, et al · · 2023 · cited 38× · PMID 36986390 · DOI 10.3390/pathogens12030468
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.
Sabeel Z, Yang Z. · · 2025 · cited 2× · PMID 41168838 · DOI 10.1186/s12943-025-02456-x
Microorganisms and Breast Cancer: An In-Depth Analysis of Clinical Studies.
Naderi N, Mosahebi A, Williams NR. · · 2023 · cited 2× · PMID 38276152 · DOI 10.3390/pathogens13010006

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03519438 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 20 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03519438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing